Canary's INJ ETF Is Live, But Read the Fine Print Before You Celebrate

Canary Capital's staked Injective ETF just started trading on Nasdaq, and the fund is keeping 30% of all staking rewards before charging you an additional 1.10% annual sponsor fee on top.

That's the number nobody is leading with. The headline is historic access. The fine print is a revenue split that heavily favors the house.

What's Actually Happening Here

The ETF gives traditional investors direct exposure to INJ, Injective Protocol's native token, with staking rewards baked in. No wallet. No seed phrase. No bridging headaches. For a certain class of institutional and retail investor, that convenience is genuinely worth something.

But the structure demands a closer look. Canary retains 70% of staking rewards generated by the fund's holdings. The remaining 30% flows through to shareholders, net of that 1.10% annual fee plus additional expenses. If staking yields compress, shareholders could end up with almost nothing after costs are stripped out.

This is not unique to Canary. Similar dynamics have played out in staked Ethereum ETF proposals. But the INJ staking structure makes the math particularly tight, and most coverage is glossing right over it.

Why This Still Matters for the INJ Market

Despite the fee mechanics, this listing is a legitimacy signal that the market will likely price in. Nasdaq listings don't happen by accident. Canary had to satisfy compliance, custody, and regulatory requirements to get here. That's real institutional infrastructure being built around Injective, a chain that has quietly processed billions in derivatives volume while the broader market fixated on Solana and Base.

ETF listings historically pull demand from spot markets. If institutional capital flows into this vehicle, the fund must hold actual INJ. That creates sustained buy pressure that doesn't show up in retail sentiment trackers.

Injective's staking participation rate is already high relative to its circulating supply. New institutional demand layered on top of that could meaningfully tighten available float.

What to Watch Right Now

INJ holders should track two things closely over the next 30 days: ETF volume on Nasdaq as a proxy for institutional appetite, and any movement in Injective's on-chain staking rate as a signal of whether retail is responding to the same narrative.

If you're holding INJ directly and staking natively, you're keeping 100% of your rewards. That's the quiet edge this ETF launch just made more obvious.

The real trade here isn't buying the ETF. It's understanding what the ETF's existence signals about where institutional money is quietly pointing next.